Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

LifeTech Scientific Corporation
先健科技公司

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1302)

TERMINATION OF THE FRAMEWORK AGREEMENT

Reference is made to the announcements of LifeTech Scientific Corporation (the "**Company**", together with its subsidiaries, the "**Group**") dated 22 May 2026 (the "**May Announcement**") and 20 July 2026 (the "**July Announcement**") in relation to the proposed acquisition of the Starway Equity and the proposed issue of Convertible Bonds under Specific Mandate (the "**Transaction**"). Unless the context otherwise requires, terms used herein shall have the same meanings as those defined in the May Announcement.

As disclosed in the July Announcement, the Board resolved not to proceed with the Transaction. The Board announces that, on 5 November 2026, the Company and the Seller entered into an agreement (the "**Agreement**"), pursuant to which the Framework Agreement shall be terminated and shall cease to have any force or effect, and each of the Company and the Seller shall be irrevocably released and discharged from all or any of its obligations and liabilities arising out of or in connection with the Framework Agreement or the Transaction (save for those under the Agreement), subject to receipt by the Seller of the costs, expenses and fee as referred to in the Framework Agreement and the May Announcement and specified in the Agreement from the Company on or before 9 November 2026.

By order of the Board
LifeTech Scientific Corporation
XIE Yuehui
Executive Director, Chairman and Chief Executive Officer

Hong Kong, 5 November 2026

As at the date of this announcement, the Board comprises Mr. XIE Yuehui, Ms. WU Liping and Mr. FANG Yu being executive Directors; and Mr. ZHOU Luming, Ms. CHEN Dongxia and Mr. JIANG Feng being independent non-executive Directors.